Binocular Vision Discovery Provides Insights for Stem Cell Therapy
A Salk Institute research team has discovered how nature controls the degree of binocular vision in mammals, work that could have crucial implications for human stem-cell medicine.
Binocular vision is possible because some nerve cells (neurons) from the retina grow into the same side of the brain during embryonic development while others cross over into the opposite side of the brain. A research group at the Salk, led by Dr. Dennis O'Leary, has now discovered that the proportion of neurons that cross over is determined by a single regulatory protein called Islet-2. The startling results were published in the journal Cell today.
Binocular vision is essential to all predatory animals, including humans, because it provides us with depth perception. Prey animals, such as many birds, have sideways-projecting eyes and virtually no binocular vision.
O'Leary's group determined that Islet-2, a protein that turns on or off other genes that control the connections between nerve cells, has a very specific role in controlling the degree of binocular vision. It suppresses two key chemical signals called Zic2 and EphB1 that ensure retinal neurons grow ipsilaterally, that is, into the same side of the brain. In genetically engineered mice without the gene for Islet-2, Zic2 and EphB1 are able to exert their effects unchallenged and a greater percentage of retinal cells connect to the same side of the brain.
Thus, using this 'genetic reostat' nature appears to be able to 'dial up or down' the degree of binocular vision required in the developing animal simply by controlling the amount of Islet-2 produced by the retina.
Dr. O'Leary's fascinating discovery may have crucial implications for stem-cell medicine for repairing damaged nerves. "If you're going to use stem cells for therapy," O'Leary said, "you need to know what genes are involved in determining and restricting their fate."
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.